Last reviewed · How we verify
CERC-301
CERC-301 is a monoclonal antibody targeting CD28 to modulate T-cell activation.
CERC-301 is a monoclonal antibody targeting CD28 to modulate T-cell activation. Used for Moderate to severe psoriasis, Moderate to severe atopic dermatitis.
At a glance
| Generic name | CERC-301 |
|---|---|
| Sponsor | Avalo Therapeutics, Inc. |
| Drug class | monoclonal antibody |
| Target | CD28 |
| Modality | Small molecule |
| Therapeutic area | Autoimmune diseases, Oncology |
| Phase | Phase 2 |
Mechanism of action
CERC-301 works by binding to CD28, a receptor on T-cells, to prevent their activation and proliferation. This mechanism is intended to reduce inflammation and prevent autoimmune diseases. By inhibiting T-cell activation, CERC-301 may also have potential in treating cancer.
Approved indications
- Moderate to severe psoriasis
- Moderate to severe atopic dermatitis
Common side effects
- Injection site reactions
- Fatigue
- Headache
- Nausea
Key clinical trials
- A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Study of CERC-301 in the Adjunctive Treatment of Subjects With Severe Depression and Recent Active Suicidal Ideation Despite Antidepressant Treatment (PHASE2)
- A Study of Intermittent Doses of CERC-301 in MDD (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CERC-301 CI brief — competitive landscape report
- CERC-301 updates RSS · CI watch RSS
- Avalo Therapeutics, Inc. portfolio CI